Home › Compare › NBIO vs EQR

NBIO vs EQR: Dividend Comparison 2026

NBIO yields 666666.67% · EQR yields 4.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NBIO wins by $8.275235618773884e+34M in total portfolio value
10 years
NBIO
NBIO
● Live price
666666.67%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8.275235618773884e+34M
Annual income
$82,727,945,429,218,320,000,000,000,000,000,000,000,000.00
Full NBIO calculator →
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →

Portfolio growth — NBIO vs EQR

📍 NBIO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNBIOEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NBIO + EQR cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
NBIO pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NBIO
Annual income on $10K today (after 15% tax)
$56,666,666.67/yr
After 10yr DRIP, annual income (after tax)
$70,318,753,614,835,575,000,000,000,000,000,000,000,000.00/yr
EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
At 15% tax rate, NBIO beats the other by $70,318,753,614,835,575,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NBIO + EQR for your $10,000?

NBIO: 50%EQR: 50%
100% EQR50/50100% NBIO
Portfolio after 10yr
$4.137617809386942e+34M
Annual income
$41,363,972,714,609,160,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.97%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

NBIO
No analyst data
Altman Z
-223.9
Piotroski
1/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NBIO buys
0
EQR buys
0
No recent congressional trades found for NBIO or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNBIOEQR
Forward yield666666.67% ✓4.73%
Annual dividend / share$2.00$2.77 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8% ✓
Portfolio after 10y$8.275235618773884e+34M$40.5K ✓
Annual income after 10y$82,727,945,429,218,320,000,000,000,000,000,000,000,000.00 ✓$3,819.61
Total dividends collected$8.275075881065991e+34M$16.9K ✓
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: NBIO vs EQR ($10,000, DRIP)

YearNBIO PortfolioNBIO Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$66,677,367$66,666,666.67$11,248$547.57+$66.67M → NBIO
2$415,506,651,117$415,435,306,334.37$12,701$666.53+$415506.64M → NBIO
3$2,419,908,598,386,268$2,419,464,006,269,573.00$14,405$814.59+$2419908598.37M → NBIO
4$13,171,697,643,084,456,000$13,169,108,340,884,183,000.00$16,413$999.84+$13171697643084.44M → NBIO
5$67,004,927,492,790,120,000,000$66,990,833,776,312,020,000,000.00$18,795$1,232.92+$67004927492790120.00M → NBIO
6$318,562,277,003,514,840,000,000,000$318,490,581,731,097,560,000,000,000.00$21,639$1,527.95+$318562277003514871808.00M → NBIO
7$1,415,484,168,853,553,000,000,000,000,000$1,415,143,307,217,159,200,000,000,000,000.00$25,057$1,903.80+$1.415484168853553e+24M → NBIO
8$5,878,130,573,362,507,000,000,000,000,000,000$5,876,616,005,301,833,000,000,000,000,000,000.00$29,197$2,385.87+$5.878130573362507e+27M → NBIO
9$22,813,793,009,840,743,000,000,000,000,000,000,000$22,807,503,410,127,248,000,000,000,000,000,000,000.00$34,250$3,008.70+$2.2813793009840744e+31M → NBIO
10$82,752,356,187,738,840,000,000,000,000,000,000,000,000$82,727,945,429,218,320,000,000,000,000,000,000,000,000.00$40,467$3,819.61+$8.275235618773884e+34M → NBIO

NBIO vs EQR: Complete Analysis 2026

NBIO — Stock

Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. In addition, the company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation. Nascent Biotech, Inc. is based in Vero Beach, Florida.

Full NBIO Calculator →

EQR — REIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this NBIO vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NBIO vs SCHDNBIO vs JEPINBIO vs ONBIO vs KONBIO vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.